LIPO vs. AWH, SNSE, PMCB, KZIA, AIM, TLPH, CDIO, WENA, IMNN, and TSBX
Should you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Aspira Women's Health (AWH), Sensei Biotherapeutics (SNSE), PharmaCyte Biotech (PMCB), Kazia Therapeutics (KZIA), AIM ImmunoTech (AIM), Talphera (TLPH), Cardio Diagnostics (CDIO), ANEW Medical (WENA), Imunon (IMNN), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry.
Lipella Pharmaceuticals vs.
Aspira Women's Health (NASDAQ:AWH) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation.
Aspira Women's Health has a net margin of -165.07% compared to Lipella Pharmaceuticals' net margin of -882.82%. Aspira Women's Health's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.
Aspira Women's Health has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.
12.2% of Aspira Women's Health shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 4.3% of Aspira Women's Health shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Aspira Women's Health received 13 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 19.44% of users gave Aspira Women's Health an outperform vote.
Aspira Women's Health currently has a consensus price target of $4.40, suggesting a potential upside of 456.96%. Lipella Pharmaceuticals has a consensus price target of $16.00, suggesting a potential upside of 417.80%. Given Aspira Women's Health's higher possible upside, analysts plainly believe Aspira Women's Health is more favorable than Lipella Pharmaceuticals.
Lipella Pharmaceuticals has lower revenue, but higher earnings than Aspira Women's Health. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aspira Women's Health had 3 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 6 mentions for Aspira Women's Health and 3 mentions for Lipella Pharmaceuticals. Aspira Women's Health's average media sentiment score of 0.74 beat Lipella Pharmaceuticals' score of 0.00 indicating that Aspira Women's Health is being referred to more favorably in the media.
Summary
Aspira Women's Health beats Lipella Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Lipella Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipella Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LIPO) was last updated on 12/5/2024 by MarketBeat.com Staff
Free LIPO Stock Alerts